Can Kerendia Cause Dehydration?
Kerendia (finerenone) does not directly cause dehydration as a primary adverse effect, but patients should be counseled about temporary treatment interruption during acute dehydrating illnesses to prevent acute kidney injury.
Understanding the Risk Profile
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, and unlike traditional diuretics or SGLT2 inhibitors, it does not have a primary mechanism that promotes fluid loss. The FDA drug label does not list dehydration as a common adverse event 1.
Key Clinical Considerations
Primary Adverse Events
The most common adverse events with finerenone are:
- Hyperkalemia (10.8-14% vs 5.3-6.9% with placebo) 2, 3, 4
- Increased blood creatinine 5, 6
- Decreased glomerular filtration rate 5, 6
- Renal impairment 5, 6
Indirect Dehydration Risk
The main concern is not that finerenone causes dehydration, but rather how dehydration from other causes interacts with finerenone therapy:
- "Sick day" management is critical: Patients must temporarily discontinue finerenone during acute dehydrating illnesses (diarrhea, vomiting, excessive sweating) to prevent acute kidney injury 7, 8
- The FDA label specifically states: "Diarrhea or other causes of dehydration should be addressed emergently" 8
- Guidelines recommend suspending finerenone during severe dehydration to avoid hypovolemia 7
Blood Pressure Effects
Finerenone causes modest blood pressure reductions:
- Mean systolic BP decrease: 2-3 mmHg
- Mean diastolic BP decrease: 1-2 mmHg 1
These changes are minimal and do not typically cause symptomatic hypotension or volume depletion in most patients. However, in elderly or frail patients with advanced age, there is a higher risk of volume depletion, making strict "sick day" education mandatory 7.
Practical Management Algorithm
Patient Education Points:
Temporarily stop finerenone if experiencing:
- Severe diarrhea or vomiting
- Inability to maintain oral fluid intake
- Excessive sweating or heat exposure
- Any acute illness causing dehydration
Resume finerenone only after:
- Adequate rehydration
- Resolution of acute illness
- Verification of stable kidney function and potassium levels
Avoid imaging agents that require high-dose iodinated contrast or gadolinium without proper hydration protocols 9
Monitoring Strategy:
- Check serum creatinine and potassium within 2-4 weeks of initiation 10
- Monitor at least monthly for the first 3 months 8
- Reassess during any intercurrent illness
Common Pitfall to Avoid
Do not confuse finerenone with SGLT2 inhibitors or loop diuretics, which do have direct diuretic effects and higher dehydration risk. Finerenone's mechanism (mineralocorticoid receptor antagonism) does not promote urinary fluid loss like these other agents 11.
The key message: Finerenone itself does not cause dehydration, but patients must be educated to hold the medication during dehydrating illnesses to prevent complications 7, 8, 9.